Search

Irit Rappley

from San Diego, CA
Age ~48
Get Report
Related to:
Warren RappleyMartha L Keefe, 66Katelyn M Carrigan, 47Deidre M Rappley, 51Lawrence DeanDan Edenfield, 63Dortha Baird, 98Shane KlinePriscilla Kline
Connected to:
Alex F Rappley, 39Andrew C Rappleyea, 37Carol G Rappley, 68Jennifer M Rappleye, 37Martin M Rappleyea, 54Pamela A Rappleye, 64Debra Rappo, 84Kathleen M Rappo, 67Christoph Rappold, 59Don W Rappold, 79

Irit Rappley Phones & Addresses

  • 5653 Carnegie St, San Diego, CA 92122
  • Jamaica Plain, MA
  • Cambridge, MA
  • 3800 Graham St, Saginaw, MI 48609 (517) 781-0570

Work

Company: Bristol-myers squibb Nov 2019 Position: Associate director, protein homeostasis, neuroscience thematic research center

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Harvard University 2004 to 2009 Specialities: Neuroscience

Skills

Biochemistry • Molecular Biology • Cell • Cell Biology • Cell Culture • Assay Development • Neuroscience • In Vitro • Confocal Microscopy • Western Blotting • Neurodegeneration • Fluorescence Microscopy • Protein Purification • Cell Based Assays • Hplc • Immunohistochemistry • Protein Expression • Biomarker Discovery • In Vivo • Biophysics • Flow Cytometry • Elisa • Mechanism of Action Studies • Facs • Research and Development • Business Development • Business Strategy • Liquid Chromatography • Animal Models • Science • Community Outreach • Fplc • Immunoprecipitation • Proteomics • Immunofluorescence • Central Nervous System • Protein Chemistry • Fret • Transfection • Sds Page • Mass Spectrometry • Pcr • Circular Dichroism • Microscopy • Molecular Cloning • Tissue Culture

Languages

Hebrew

Industries

Research

Resumes

Resumes

Irit Rappley Photo 1

Associate Director, Protein Homeostasis, Neuroscience Thematic Research Center

View page
Location:
312 Windemere Woods Dr, Nashville, TN 37215
Industry:
Research
Work:
Bristol-Myers Squibb
Associate Director, Protein Homeostasis, Neuroscience Thematic Research Center
Celgene Jun 2014 - Jan 2015
Scientist
The Scripps Research Institute Dec 2009 - Jun 2014
Postdoctoral Research Associate
Celgene Dec 2009 - Jun 2014
Protein Homeostasis Lead For Neuroscience
Brigham and Women's Hospital Jun 2009 - Nov 2009
Postdoctoral Research Associate
Education:
Harvard University 2004 - 2009
Doctorates, Doctor of Philosophy, Neuroscience Massachusetts Institute of Technology 2000 - 2004
Bachelors, Linguistics Harvard University 1965 - 1971
Doctorates, Doctor of Philosophy
Skills:
Biochemistry
Molecular Biology
Cell
Cell Biology
Cell Culture
Assay Development
Neuroscience
In Vitro
Confocal Microscopy
Western Blotting
Neurodegeneration
Fluorescence Microscopy
Protein Purification
Cell Based Assays
Hplc
Immunohistochemistry
Protein Expression
Biomarker Discovery
In Vivo
Biophysics
Flow Cytometry
Elisa
Mechanism of Action Studies
Facs
Research and Development
Business Development
Business Strategy
Liquid Chromatography
Animal Models
Science
Community Outreach
Fplc
Immunoprecipitation
Proteomics
Immunofluorescence
Central Nervous System
Protein Chemistry
Fret
Transfection
Sds Page
Mass Spectrometry
Pcr
Circular Dichroism
Microscopy
Molecular Cloning
Tissue Culture
Languages:
Hebrew

Publications

Us Patents

Treatment Of A Hematologic Malignancy With 2-(4-Chlorophenyl)-N-((2-(2,6-Dioxopiperidin-3-Yl)-1-Oxoisoindolin-5-Yl)Methyl)-2,2-Difluoroacetamide

View page
US Patent:
20190175573, Jun 13, 2019
Filed:
Feb 13, 2019
Appl. No.:
16/275234
Inventors:
- Summit NJ, US
Paul Hollenbach - Castro Valley CA, US
Kyle MacBeth - San Francisco CA, US
Michael Pourdehnad - San Francisco CA, US
Irit Rappley - San Diego CA, US
Gang Lu - San Diego CA, US
International Classification:
A61K 31/454
A61K 9/19
A61K 9/00
Abstract:
Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.

Treatment Of A Hematologic Malignancy With 2-(4-Chlorophenyl)-N-((2-(2,6-Dioxopiperidin-3-Yl)-1-Oxoisoindolin-5-Yl)Methyl)-2,2-Difluoroacetamide

View page
US Patent:
20170348298, Dec 7, 2017
Filed:
Jun 5, 2017
Appl. No.:
15/614434
Inventors:
- Summit NJ, US
Paul Hollenbach - Castro Valley CA, US
Kyle MacBeth - San Francisco CA, US
Michael Pourdehnad - San Francisco CA, US
Irit Rappley - San Diego CA, US
International Classification:
A61K 31/454
A61K 9/19
Abstract:
Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)--oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.
Control profile
Irit Rappley from San Diego, CA, age ~48 Get Report